Page 1 of 15
(https://www.aetna.com/)
Hematopoietic Cell Transplantation for Ovarian Cancer
Clinical Policy Bulletins Medical Clinical Policy Bulletins
Policy History
Last
Review
03/01/2019
Effective: 08/16/200
Next Review:
06/27/2019
Review History
Definitions
Additional
Number: 0635
Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB.
I. Aetna considers autologous hematopoietic cell transplantation medically
necessary for the treatment of persons with relapsed germ cell tumors of
the ovary that were responsive to standard chemotherapy.
II. Aetna considers autologous hematopoietic cell transplantation medically
necessary as consolidation therapy for persons with germ cell tumors of the
ovary that is in complete remission.
III. Aetna considers tandem autologous hematopoietic cell
transplantation medically necessary for persons with germ cell tumors of
the ovary that is in relapse.
IV. Aetna considers autologous hematopoietic cell
transplantation experimental and investigational when used as initial
treatment (i.e., instead of an initial course of standard-dose chemotherapy
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019
Page 2 of 15
with Food and D rug Administration (FDA)-approved drugs) of persons with
germ cell tumors of the ovary because its effectiveness for this indication
has not been established.
V. Aetna considers allogeneic hematopoietic cell transplantation experimental
and investigational for the treatment of persons with germ cell tumors of
the ovary because its effectiveness for this indication has not been
established.
VI. Aetna considers hematopoietic cell transplantation (autologous or
allogeneic) experimental and investigational for the treatment of persons
with epithelial ovarian cancers because its effectiveness for this indication
has not been established.
Background
Ovarian cancer is the leading cause of death among gynecological malignancies
and the 4th leading cause of cancer death in American women. Each year about
25,400 new cases of ovarian cancer are diagnosed and 14,500 women die from the
disease. Approximately 90 % of all ovarian cancers are epithelial ovarian
carcinomas arising from the germinal epithelium of the ovary. The remaining 10 %
of ovarian malignancies consist of germ cell origin, stromal and sex cord tumors.
Epithelial ovarian cancer accounts for 4 % of all cancers in women. Germ cell
tumors of the ovary are uncommon but aggressive tumors seen most often in
young women or adolescent girls. About 50 % of germ cell malignancies are pure
dysgerminomas; and about 70 % of dysgerminomas are confined to the ovary at
diagnosis.
The most important risk factor for ovarian cancer is a family history of a 1st-degree
relative with the disease. Approximately 5 to 10 % of ovarian cancers are familial
and there is increasing evidence that there are a small number of families at
particularly high-risk for developing epithelial ovarian cancer. Three distinct
hereditary syndromes associated with the occurrence of familial ovarian cancer
have been identified: (i) ovarian cancer syndrome, (ii) hereditary breast-ovarian
cancer syndrome, and (iii) Lynch II syndrome, which includes a predisposition
to ovarian, endometrial, and colon cancers. All 3 syndromes exhibit an
autosomal dominant pattern of transmission with variable penetrance.
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019
Page 3 of 15
Since early stage ovarian cancer has no major associated symptoms and there are
no reliable screening tests, the majority of patients present with metastatic disease
throughout the peritoneal cavity. In the United States, nearly 70 % of the 23,000
patients diagnosed annually with epithelial ovarian cancer present with advanced
disease -- International Federation of Gynecology and Obstetrics (FIGO) stages III
to IV. The FIGO staging for primary ovarian carcinoma is as follows:
Table: Stages of Primary Ovarian Carcinoma
The prognosis of ovarian cancer is influenced by several factors including stage at
presentation, size of residual tumor following initial surgery, histologic grade, patient
performance status and age. The 5-year survival rate for patients with advanced
ovarian cancer treated with conventional therapy were only 15 to 25 % for stage III
disease and less than 5 % for stage IV disease.
All stages of ovarian cancer are first treated with cytoreductive surgery, including
oophorectomy and total abdominal hysterectomy. Unilateral oophorectomy is
adequate treatment for most patients with stage I and stage II diseases. The
objective of surgery in disease stages later than stage I is to reduce the bulk of the
largest residual tumor deposit to less than 1 or 2 cm for optimal disease prognosis.
While this may be sufficient treatment for cases confined to the ovary, typically intra-
peritoneal spread is identified; thus, surgery is commonly followed by chemotherapy.
Paclitaxel/platinum combinations are the standard 1st-line chemotherapy. The extent
of chemotherapy treatment varies with the stage of disease. Ovarian cancers are
responsive to chemotherapy in 80 to 90 % of cases, and the success of
chemotherapy is dependent on the volume of disease that remains after
cytoreductive surgery. Salvage chemotherapy with several single
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019
Page 4 of 15
agents has only modest activity and does not extend survival of patients with
relapsed ovarian carcinoma. Sex cord-stromal tumors can occur at any point in a
woman's life. Because of the rarity of sex cord-stromal tumors, there is no
established chemotherapeutic regimen.
Multiple uncontrolled studies have examined the effectiveness of single and
multiple cycles of high-dose chemotherapy (HDC) with stem cell support (peripheral
stem cells or autologous bone marrow transplantation) in patients with advanced
and chemo-resistant epithelial ovarian cancer. High-dose chemotherapy with
autologous stem cell transplantation is still investigational for patients with epithelial
ovarian cancer.
In a review on HDC for the management of patients with ovarian cancer, McGuire
(2000) noted that the effect of HDC (including stem cell-supported HDC) on the
survival of women with ovarian cancer has been examined in numerous clinical
studies. The data demonstrated increased response rates with high-dose
regimens, but any survival advantages observed have been limited. Patients with
the most favorable outcome were those with low tumor burden and chemotherapy-
sensitive tumors. An attempt to study this group of patients in a randomized trial in
the United States (Gynecologic Oncology Group Protocol 164) was unsuccessful
because of low accrual. European randomized trials are under way to evaluate
HDC and stem cell transplantation as part of initial therapy or as consolidation after
initial response to therapy and to compare HDC with standard-dose chemotherapy.
Until results from these studies become available, HDC remains limited to the
clinical trial setting.
In a phase I clinical trial, Donato and associates (2001) examined the effectiveness
of HDC with autologous stem cell support for the treatment of women with
advanced ovarian cancer (n = 53). All patients had refractory and/or recurrent
ovarian cancer and had been previously treated with paclitaxel and platinum. The
overall response rate in the 30 patients with measurable or evaluable disease was
93 %. It was reported that toxicity was acceptable and there were no treatment-
related deaths. The authors concluded that in the setting of ovarian cancer, high-
dose regimens should be administered only as part of a well-designed clinical trial.
In a retrospective study, Ledermann and colleagues (2001) analyzed the outcome
of patients with advanced or recurrent epithelial ovarian cancer (n = 254) treated
with HDC -- 105 received HDC in complete or very good partial remission, 27 in
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019
Page 5 of 15
second remission and 122 in the presence of residual disease. Most received
melphalan or carboplatin, or a combination (86 %) supported by autologous bone
marrow or peripheral blood stem cells. The survival of patients treated in remission
was significantly better than in other groups (median 33 versus 14 months). The
durability of remission was longer after transplantation in first remission than in
second remission (median disease-free survival 18 versus 9 months). With a
median follow-up of 76 months from diagnosis, the median disease-free and overall
survival (OS) in stage III disease transplanted in remission is 42 and 59 months and
for stage IV disease 26 and 40 months, respectively. The authors concluded that
HDC has a potential benefit for patients in remission. The results support the
conduct of randomized studies to determine whether there is a real value from this
treatment.
In a review on 2nd-line and subsequent therapy for ovarian carcinoma,
Peethambaram and Long (2002) stated that HDC with autologous stem cell
transplantation is still investigational. Women with advanced ovarian carcinoma
should continue to be encouraged to participate in well-designed clinical trials.
The European Group for Blood and Marrow Transplantation (Urbano-Ispizua et al,
2002) recently stated that for ovarian cancer with minimal residue disease,
allogeneic transplantation is not generally recommended; while autologous
transplantation may be undertaken in approved clinical protocols -- the value of
transplants for patients included in this category needs further investigation. For
refractory ovarian cancer, allogeneic transplantation using sibling donor is
developmental (there is very little experience with this particular type of transplant);
while allogeneic transplantation using alternative donor or autologous
transplantation is not generally recommended. For relapsed germ cell tumors that
were sensitive to chemotherapy, allogeneic transplantation is not generally
recommended, while autologous transplantation is standard use in selected
patients. For refractory germ cell tumors, allogeneic transplantation is not generally
recommended; while autologous transplantation may be undertaken in approved
clinical protocols.
Schilder et al (2003) stated that HDC (supported by hematopoietic stem cells) as 1st-
line treatment for epithelial ovarian cancer remains experimental and should be
restricted to clinical trials.
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019
Page 6 of 15
Bengala et al (2005) reported that HDC with autologous hemopoietic support does
not benefit patients with advanced epithelial ovarian cancer in first complete
remission.
In a phase II multi-center study, Goncalves and colleagues (2006) assessed the
feasibility, toxicity and effectiveness of post-operative front-line sequential HDC with
hematopoietic stem cell (HSC) support in patients with advanced ovarian cancer
(AOC). A total of 34 patients with stage IIIC/IV epithelial ovarian cancer received a
post-operative sequential combination of high-dose cyclophosphamide/epirubicin
(D1, D21) with HSC harvesting, high-dose carboplatin (D42, D98) followed by HSC
infusion, and dose-dense paclitaxel (D63, D77, D119, D133). Rh-G-CSF (filgrastim)
was administered following all cycles. Primary endpoint was pathological complete
response rate (pCR). A total of 30 patients received at least 7 of the scheduled 8
cycles. Hematological toxicity was significant but manageable. Grade 3/4 extra-
hematopoietic toxicities were relatively uncommon and reversible. No toxicity-
related death was observed. The observed pCR was 37 % and did not reach the
initial endpoint. Post-operative front-line sequential HDC in AOC is feasible and
safe in a multi-center setting. The observed pCR does not support a clear
advantage over conventional treatment. The authors concluded that regarding the
high level of toxicity encountered, this approach should not be performed outside
clinical trials, and remains an experimental strategy to further optimize and validate.
In a multi-center phase I/II clinical study, Frickhofen and colleagues (2006)
assessed the effectiveness of multi-cycle (also known as sequential) HDC with
autologous peripheral blood stem cell support for the treatment of patients with
advanced ovarian cancer. A total of 48 subjects with untreated ovarian cancer
were enrolled in this trial. Median age was 46 (19 to 59 years); International FIGO-
stage was III in 79 % and IV in 21 %; 31 % had residual disease greater than 1 cm
after surgery. Two courses of induction/mobilization therapy with
cyclophosphamide (250 mg/m2) and paclitaxel (250 mg/m2) were used to collect
peripheral blood stem cells. High-dose chemotherapy consisted of 2 courses of
carboplatin (area under curve (AUC) 18-22) and paclitaxel followed by 1 course of
carboplatin and melphalan (140 mg/m2) with or without etoposide (1,600 mg/m2).
Main toxicity was gastrointestinal. Limiting carboplatin to AUC 20 and eliminating
etoposide resulted in manageable toxicity (69 % without grade 3/4 toxicity). One
patient died from treatment-related pneumonitis. At 8 years median follow-up,
median progression-free-survival (PFS) and OS is 13.3 and 37.0 months. Five-
years PFS and OS are 18 and 33 %, respectively. The authors noted that multi-
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019
Page 7 of 15
cycle HDC is feasible in a multi-center setting, and a European phase III trial based
on this regimen examining the effectiveness of multi-cycle HDC has been
completed. Preliminary findings do not suggest an improvement of OS or PFS with
multi-cycle HDC compared to standard dose chemotherapy. They stated that multi-
cycle HDC should thus be considered experimental in ovarian cancer.
Mobus and colleagues (2007) compared sequential HDC with peripheral blood
stem cell (PBSC) support with platinum-based combination chemotherapy to
ascertain if dose-intensification improves outcome. A total of 149 patients with
untreated ovarian cancer were randomly assigned after debulking surgery to
receive standard combination chemotherapy or sequential HDC with 2 cycles of
cyclophosphamide and paclitaxel followed by 3 cycles of high-dose carboplatin and
paclitaxel with PBSC support. High-dose melphalan was added to the final cycle.
The median age was 50 years (range of 20 to 65) and International Federation of
Gynecology and Obstetrics stage was IIb/IIc in 4 %, III in 78 %, and IV in 17 %.
Seventy-six percent of patients received all 5 cycles in the high-dose arm and the
main toxicities were neurotoxicity/ototoxicity, gastrointestinal toxicity, and infection
and 1 death from hemorrhagic shock. After a median follow-up of 38 months, the
PFS was 20.5 months in the standard arm and 29.6 months in the high-dose arm
(hazard ratio [HR], 0.84; 95 % confidence interval [CI]: 0.56 to 1.26; p, 0.40).
Median OS was 62.8 months in the standard-arm and 54.4 months in the HD-arm
(HR, 1.17; 95 % CI: 0.71 to 1.94; p, 0.54). The authors stated that this is the first
randomized trial comparing sequential HDC versus standard-dose chemotherapy in
1st-line treatment of patients with advanced ovarian cancer. They observed no
statistically significant difference in PFS or OS and concluded that HDC does not
appear to be superior to conventional dose chemotherapy.
Bay and colleagues (2010) stated that although preliminary results suggested that
allogeneic hematopoietic stem cell transplantation (allo HCT) for ovarian cancer
(OC) is a feasible procedure, the low patient number in previous studies had limited
ability to evaluate the true benefit of allo HCT in OC. This retrospective multi-center
study included 30 patients with OC allografted between 1995 and 2005 to
determine the outcome of patients with OC treated with allo HCT. Prior to allo
HCT, patients were in complete response (n = 1), partial response (n = 7), stable
disease (n = 11) or had progressive disease (n = 13). An objective response (OR)
was observed in 50 % (95 % CI: 33 to 67) of patients. Three patients of responding
patients had an OR following the development of acute graft-versus-host disease
(aGVHD). The cumulative incidence of chronic GVHD (cGVHD) was 34 % (95 %
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019
Page 8 of 15
CI: 18 to 50). Transplant relative mortality rates were 7 and 20 % on day 100 and 1
year, respectively. With a median follow-up of 74.5 months (range of 16 to 148),
median PFS was 6 months and median OS was 10.4 months. Patients who
developed cGVHD following allo HCT had a significant OS improvement compared
to those who did not (17.6 months versus 6.5 months, p = 0.042). However, PFS
was n ot similarly s ignificantly improved in patients who developed cGVHD (12
months versus 3.7 months, p = 0.81). The authors concluded that Allo HCT in OC
may lead to graft-versus-OC effects. Their clinical relevance remains to be shown.
In a phase II clinical trial, Geller et al (2010) evaluated the tumor response and in-
vivo expansion of allogeneic natural killer (NK) cells in recurrent ovarian and breast
cancer. Patients underwent a lympho-depleting preparative regimen: fludarabine
25 mg/m(2) × 5 doses, cyclophosphamide 60 mg/kg × 2 doses, and, in 7 patients,
200 cGy total body irradiation (TBI) to increase host immune suppression. An NK
cell product, from a haplo-identical related donor, was incubated over-night in 1,000
U/ml interleukin (IL)-2 prior to infusion. Subcutaneous IL-2 (10 MU) was given 3
times/week × 6 doses after NK cell infusion to promote expansion, defined as
detection of greater than or equal to 100 donor-derived NK cells/μL blood 14 days
after infusion, based on molecular chimerism and flow cytometry. A total of 20
patients (14 ovarian cancer, 6 breast cancer) were enrolled. The median age was
52 (range of 30 to 65) years. Mean NK cell dose was 2.16 × 10(7)cells/kg. Donor
DNA was detected 7 days after NK cell infusion in 9/13 (69 %) patients without TBI
and 6/7 (85 %) with TBI. T-regulatory cells (Treg) were elevated at day +14
compared with pre-chemotherapy (p = 0.03). Serum IL-15 levels increased after
the preparative regimen (p < 0.001). Patients receiving TBI had delayed
hematologic recovery (p = 0.014). One patient who was not evaluable had
successful in-vivo NK cell expansion. The authors concluded that adoptive transfer
of haplo-identical NK cells after lympho-depleting chemotherapy is associated with
transient donor chimerism and may be limited by reconstituting recipient Treg cells.
They stated that strategies to augment in-vivo NK cell persistence and expansion
are needed.
De Giorgi and colleagues (2017) noted that a few small retrospective series
reported results with salvage chemotherapy for malignant ovarian adult-type
granulosa cell tumors (GCTs), whereas no data are available on the use of HDC
with hematopoietic progenitor cell support (HSCS) in these patients. These
researchers analyzed the available data of HDC for adult-type GCTs. They
conducted a retrospective analysis of ovarian cancer treated with salvage HDC
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019
Page 9 of 15
registered with the European Society for Blood and Marrow Transplantation. Of
203 adult female patients with a diagnosis of non-epithelial ovarian cancer treated
with salvage HDC with HSCS and registered with the European Society for Blood
and Marrow Transplantation, 4 (2 %) patients were affected by GCTs. All 4
patients had ovarian adult-type GCTs that relapsed/progressed after 1st-line
chemotherapy. The conditioning regimens included a platinum agent in all 4
patients. Bone marrow recovery was promptly achieved; neither treatment-related
deaths or life-threatening toxicities occurred. At a median follow-up of 8.5 months,
all patients reported a progressive disease. The patient who underwent multi-cycle
HDC enjoyed a long-term remission of 84 months before progression and was the
only one alive after 94+ months. The authors concluded that these findings
showed for the first time a case with long-lasting response to salvage treatment in
adult-type GCTs using multi-cycle HDC and HSCS. These findings need to be
validated by well-designed studies.
Furthermore, an UpToDate review on “Medical treatment for relapsed epithelial
ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease” (Birrer and
Fujiwara, 2017) does not mention hematopoietic cell transplantation as a
therapeutic option.
CPT Codes / HCPCS Codes / ICD-10 Codes
Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":
CPT codes covered if selection criteria are met:
CPT codes not covered for indications in the CPB:
38205 Blood-derived hematopoietic progenitor cell harvesting for
transplantation, per collection; allogenic
38240 Hematopoietic progenitor cell (HPC); allogeneic transplantation per
donor
Other CPT codes related to the CPB:
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019
HCPCS codes covered if selection criteria are met:
ICD-10 codes covered if selection criteria are met:
C57.4
Page 10 of 15
The above policy is based on the following references:
1. Droz JP, Pico JL, Ghosn M, et al. Long-term survivors after salvage high dose
chemotherapy with bone marrow rescue in refractory germ cell cancer. Eur J
Cancer. 1991;27(7):831-835.
2. Broun ER, Nichols CR, Kneebone P, et al. Long-term outcome of patients
with relapsed and refractory germ cell tumors treated with high-dose
chemotherapy and autologous bone marrow rescue. Ann Intern Med.
1992;117(2):124-128.
3. Cannistra SA. Cancer of the ovary. N Engl J Med. 1993;329(21):1550-1559.
4. Lotz JP, Andre T, Donsimoni R, et al. High dose chemotherapy with
ifosfamide, carboplatin, and etoposide combined with autologous bone
marrow transplantation for the treatment of poor-prognosis germ cell
tumors and metastatic trophoblastic disease in adults. Cancer. 1995;75
(3):874-885.
5. Margolin BK, Doroshow JH, Ahn C, et al. Treatment of germ cell cancer with
two cycles of high-dose ifosfamide, carboplatin, and etoposide with
autologous stem-cell support. J Clin Oncol. 1996;14(10):2631-2637.
6. Weaver CH, Greco FA, Hainsworth JD, et al. A phase I-II study of high-dose
melphalan, mitoxantrone and carboplatin with peripheral blood stem cell
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019
Page 11 of 15
support in patients with advanced ovarian or breast carcinoma. Bone
Marrow Transplant. 1997;20(10):847-853.
7. Stiff PJ, Bayer R, Kerger C, et al. High-dose chemotherapy with autologous
transplantation for persistent/relapsed ovarian cancer: A multivariate
analysis of survival for 100 consecutively treated patients. J Clin Oncol.
1997;15(4):1309-1317.
8. Legros M, Dauplat J, Fleury J, et al. High-dose chemotherapy with
hematopoietic rescue in patients with stage III to IV ovarian cancer: Long
term results. J Clin Oncol. 1997;15(4):1302-1308.
9. Fennelly DW, Aghajanian C, Shapiro F, et al. Dose escalation of paclitaxel
with high-dose carboplatin using peripheral blood progenitor cell support
in patients with advanced ovarian cancer. Semin Oncol. 1997;24(1 Suppl
2):S2-26-S2-30.
10. Pecorelli S, Odicini F, Maisonneuve P et al. FIGO annual report of the
results of treatment in gynaecological cancer: Carcinoma of the ovary. J
Epidemiol Biosta. 1998;3:75-102.
11. Holmberg LA, Demirer T, Rowley S, et al. High-dose busulfan, melphalan
and thiotepa followed by autologous peripheral blood stem cell (PBSC)
rescue in patients with advanced stage III/IV ovarian cancer. Bone Marrow
Transplant. 1998;22(7):651-659.
12. Aghajanian C, Fennelly D, Shapiro F, et al. Phase II study of “dose-dense”
high-dose chemotherapy treatment with peripheral-blood progenitor-cell
support as primary treatment for patients with advanced ovarian cancer. J
Clin Oncol. 1998;16(5):1852-1860.
13. Mandanas RA, Saez RA, Epstein RB, et al. Long-term results of autologous
marrow transplantation for relapsed or refractory male or female germ
cell tumors. Bone Marrow Transplant. 1998;21(6):569-576.
14. McGuire WP. High-dose chemotherapy and autologous bone marrow or
stem cell reconstitution for solid tumors. Curr Probl Cancer. 1998;22
(3):135-177.
15. Bonnefoi H, A'Hern RP, Fisher C, et al. Natural history of stage IV epithelial
ovarian cancer. J Clin Oncol. 1999;17(3):767-775.
16. Sobecks RM, Vogelzang N J. High dose chemotherapy with autologous
stem-cell support for germ cell tumors. A critical review. Semin Oncol.
1999;26:106-118.
17. McGuire WP 3rd. High-dose chemotherapeutic approaches to ovarian
cancer management. Semin Oncol. 2000;27(3 Suppl 7):41-46.
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019
Page 12 of 15
18. Donato ML, Gershenson DM, Wharton JT, et al. High-dose topotecan,
melphalan, and cyclophosphamide (TMC) with stem cell support: A new
regimen for the treatment of advanced ovarian cancer. Gynecol Oncol.
2001;82:420-426.
19. Ledermann JA, Herd R, Maraninchi D, et al. High-dose chemotherapy for
ovarian carcinoma: Long-term results from the Solid Tumour Registry of
the European Group for Blood and Marrow Transplantation (EBMT). Ann
Oncol. 2001;12(5):693-699.
20. Trimble EL, Wright J, Christian MC. Treatment of platinum-resistant ovarian
cancer. Expert Opin Pharmacothe. 2001;2(8):1299-1306.
21. Peethambaram PP, Long HJ. Second-line and subsequent therapy for
ovarian carcinoma. Curr Oncol Rep. 2002;4(2):159-164.
22. Ozols RF. Future directions in the treatment of ovarian cancer. Semin
Oncol. 2002;29(1 Suppl 1):32-42.
23. De Giorgi U, Rosti G, Papiani G, et al. The status of high-dose
chemotherapy with hematopoietic stem cell transplantation in germ cell
tumor patients. Haematologica. 2002;87(1):95-104.
24. Urbano-Ispizua A, Schmitz N, de Witte et al. Allogeneic and autologous
transplantation for haematological diseases, solid tumors and immune
disorders: Definitions and current practice in Europe. Bone Marrow
Transplantation. 2002;29:639-646.
25. Schilder RJ, Brady MF, Spriggs D, Shea T. Pilot evaluation of high-dose
carboplatin and paclitaxel followed by high-dose melphalan supported by
peripheral blood stem cells in previously untreated advanced ovarian
cancer: A gynecologic oncology group study. Gynecol Oncol. 2003;88
(1):3-8.
26. Australian Cancer Network and National Breast Cancer Centre. Clinical
practice guidelines for the management of women with epithelial ovarian
cancer. Camperdown, VIC: National Breast Cancer Centre; March 18, 2004.
27. Stiff PJ, Shpall EJ, Liu PY, et al. Randomized Phase II trial of two high-dose
chemotherapy regimens with stem cell transplantation for the treatment
of advanced ovarian cancer in first remission or chemosensitive relapse: A
Southwest Oncology Group study. Gynecol Oncol. 2004;94(1):98-106.
28. Bengala C, Guarneri V, Ledermann J, et al. High-dose chemotherapy with
autologous haemopoietic support for advanced ovarian cancer in first
complete remission: Retrospective analysis from the Solid Tumour
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019
Page 13 of 15
Rergistry of the European Group for Blood and Marrow Transplantation
(EBMT). Bone Marrow Transplantation. 2005;36(1):25-31.
29. Tiersten A, Selleck M, Smith DH, et al. Phase I/II study of tandem cycles of
high-dose chemotherapy followed by autologous hematopoietic stem cell
support in women with advanced ovarian cancer. Int J Gynecol Cancer.
2006;16(1):57-64.
30. Goncalves A, Delva R, Fabbro M, et al. Post-operative sequential high-dose
chemotherapy with haematopoietic stem cell support as front-line
treatment in advanced ovarian cancer: A phase II multicentre study. Bone
Marrow Transplant. 2006;37(7):651-659.
31. Frickhofen N, Berdel WE, Opri F, et al; German Study Groups
Arbeitsgemeinschaft Internistische Onkologie (AIO); Arbeitsgemeinschaft
Gynakologische Onkologie (AGO). Phase I/II trial of multicycle high-dose
chemotherapy with peripheral blood stem cell support for treatment of
advanced ovarian cancer. Bone Marrow Transplant. 2006;38(7):493-499.
32. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of
conventional-dose chemotherapy with or without high-dose
chemotherapy and autologous hematopoietic stem-cell rescue as first-line
treatment for patients with poor-prognosis metastatic germ cell tumors. J
Clin Oncol. 2007;25(3):247-256.
33. Pedrazzoli P, Rosti G, Secondino S, et al; European Group for Blood and
Marrow Transplantation; Solid Tumors Working Party; Gruppo Italiano per
il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia
Cellulare. High-dose chemotherapy with autologous hematopoietic stem
cell support for solid tumors in adults. Semin Hematol. 2007;44(4):286
295.
34. Möbus V, Wandt H, Frickhofen N, et al. Phase III trial of high-dose
sequential chemotherapy with peripheral blood stem cell support
compared with standard dose chemotherapy for first-line treatment of
advanced ovarian cancer: Intergroup trial of the AGO-Ovar/AIO and EBMT.
J Clin Oncol. 2007;25(27):4187-4193.
35. Papadimitriou C, Dafni U, Anagnostopoulos A, et al. High-dose melphalan
and autologous stem cell transplantation as consolidation treatment in
patients with chemosensitive ovarian cancer: Results of a single-institution
randomized trial. Bone Marrow Transplant. 2008;41(6):547-554.
36. Nayl B, Cabrespine-Faugeras A, Maliki Y, Bay JO. Place of autologous and
allogeneic hematopoietic stem cell transplantation in ovarian cancer. Bull
Cancer. 2009;96(12):1225-1232.
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019
Page 14 of 15
37. Imrie K, Rumble RB, Crump M; Advisory Panel on Bone Marrow and Stem
Cell Transplantation, and the Hematology Disease Site Group. Cancer Care
Ontario Program in Evidence-based Care. Stem cell transplantation in
adults. Recommendations Report. Toronto, ON: Cancer Care Ontario;
2009.
38. Bay JO, Cabrespine-Faugeras A, Tabrizi R, et al. Allogeneic hematopoietic
stem cell transplantation in ovarian cancer-the EBMT experience. Int J
Cancer. 2010;127(6):1446-1452.
39. Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural
killer cell therapy to treat patients with recurrent ovarian and breast
cancer. Cytotherapy. 2011;13(1):98-107.
40. De Giorgi U, Nicolas-Virelizier E, Badoglio M, et al. High-dose
chemotherapy for adult-type ovarian granulosa cell tumors: A
retrospective study of the european society for blood and marrow
transplantation. Int J Gynecol Cancer. 2017;27(2):248-251.
41. Birrer MJ, Fujiwara K. Medical treatment for relapsed epithelial ovarian,
fallopian tubal, or peritoneal cancer: Platinum-resistant disease. UpToDate
[online serial]. Waltham, MA: UpToDate; reviewed April 2017.
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019
Page 15 of 15
Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan
benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial,
general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care
services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in
private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible
for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to
change.
Copyright © 2001-2019 Aetna Inc.
http://www.aetna.com/cpb/medical/data/600_699/0635.html 09/25/2019 Proprietary
AETNA BETTER HEALTH® OF PENNSYLVANIA
Amendment to Aetna Clinical Policy Bulletin Number: 0635 Hematopoietic
Cell Transplantation for Ovarian Cancer
There are no amendments for Medicaid.
www.aetnabetterhealth.com/pennsylvania annual 10/01/2019
Top Related